Nexsen

StrepSure is Nexsen’s rapid point-of-care diagnostic in development for detecting Group B Streptococcus in expectant mothers closer to delivery.

Nexsen’s portfolio of rapid point-of-care diagnostics covers human health, food safety, animal health, and biosecurity.

Nexsen’s diagnostics pipeline includes tests for maternal health, kidney disease, traumatic brain injury, neonatal sepsis, food safety, and biosecurity.

Nexsen operates an international research network in Australia and Asia, featuring dedicated facilities and partnerships with universities and clinicians.

Professor Vipul Bansal speaks with 2CC Canberra about Nexsen’s breakthrough kidney-disease diagnostics and how nanobiotech innovation could transform patient care.

The page introduces Nexsen’s leadership and advisory team, which includes experience in diagnostics, healthcare, clinical research, science, and commercialization.

Dis

Nexsen develops rapid point-of-care tests for serious conditions where faster diagnosis is critical.

Contact Nexsen for corporate, partnership and general enquiries relating to the Company and its growing portfolio of rapid point-of-care diagnostics.

Nexsen is developing rapid point-of-care diagnostics for serious conditions, including Group B Streptococcus, kidney disease and other unmet clinical needs.

Nexsen Limited advances its kidney diagnostics program with a planned **mid-2027 FDA submission for RenalSure®**, a bedside test for kidney assessment. The company also initiates a **feasibility study with GENSPEED Biotech GmbH** to evaluate a cartridge-based acute kidney injury test, expanding its diagnostic pipeline.

Nov 2026KalkineNews article

Nano-biotech startup **Nexsen Ltd** saw its shares surge over **37%** on debut after raising **$8 million** in its initial public offering (IPO). The company’s lab-free testing technology attracted investor interest in Australia’s growing medtech sector. Nexsen’s IPO highlights rising demand for early-stage biotech firms developing rapid diagnostic solutions.

Oct 2025Proactive InvestorsNews article

Nexsen Limited, an Australian nano-biotechnology firm, begins trading on the ASX after raising **$8 million** in its **Initial Public Offering (IPO)**. The company specializes in developing a **point-of-care diagnostic platform** for rapid medical testing. The capital raise supports its expansion and commercialization efforts in the biotech sector.

Oct 2025MedianetNews article

RMIT University researchers collaborate with Nexsen Limited to develop next-generation blood tests for earlier kidney disease detection and at-home monitoring. The $1.125 million partnership aims to advance manufacturing of these diagnostic tools. Nexsen Limited is an Australian diagnostic company specializing in medical testing innovations.

Oct 2025Australian ManufacturingNews article